Compositions and methods for cancer expressing PDE3A or SLFN12

US11207320B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• DANA-FARBER CANCER INSTITUTE, INC. · US
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Luc De Waal · Medford, US
• Matthew Meyerson · Concord, US
• Heidi Greulich · Cambridge, US
• Monica Schenone · Sharon, US
• Alex Burgin · Cambridge, US
• Xiaoyun Wu · Chesterfield, US
• Ulrike Sack · Berlin, DE

Key dates

• Filing date: Aug 12, 2016
• Grant date: Dec 28, 2021
• Expiry date: Aug 12, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).